These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

285 related articles for article (PubMed ID: 24252190)

  • 21. Immunohistochemistry is highly sensitive and specific for detecting the BRAF V600E mutation in papillary thyroid carcinoma.
    Sun J; Zhang J; Lu J; Gao J; Lu T; Ren X; Duan H; Liang Z
    Int J Clin Exp Pathol; 2015; 8(11):15072-8. PubMed ID: 26823846
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Detection of the BRAF V600E mutation in serous ovarian tumors: a comparative analysis of immunohistochemistry with a mutation-specific monoclonal antibody and allele-specific PCR.
    Bösmüller H; Fischer A; Pham DL; Fehm T; Capper D; von Deimling A; Bonzheim I; Staebler A; Fend F
    Hum Pathol; 2013 Mar; 44(3):329-35. PubMed ID: 23089489
    [TBL] [Abstract][Full Text] [Related]  

  • 23. VE1 immunohistochemical detection of the BRAF V600E mutation in thyroid carcinoma: a review of its usefulness and limitations.
    Na JI; Kim JH; Kim HJ; Kim HK; Moon KS; Lee JS; Lee JH; Lee KH; Park JT
    Virchows Arch; 2015 Aug; 467(2):155-68. PubMed ID: 25894433
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Clinical neuropathology practice news 2-2012: BRAF V600E testing.
    Capper D; Berghoff AS; von Deimling A; Preusser M
    Clin Neuropathol; 2012; 31(2):64-6. PubMed ID: 22385786
    [TBL] [Abstract][Full Text] [Related]  

  • 25. BRAF VE1 immunoreactivity patterns in epithelioid glioblastomas positive for BRAF V600E mutation.
    Kleinschmidt-DeMasters BK; Aisner DL; Foreman NK
    Am J Surg Pathol; 2015 Apr; 39(4):528-40. PubMed ID: 25581727
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Usefulness of immunohistochemistry for the detection of the BRAF V600E mutation in ovarian serous borderline tumors.
    Hayashi Y; Sasaki H; Takeshita S; Nishikawa R; Nishikawa H; Arakawa A; Yamashita Y; Takahashi S; Sugiura-Ogasawara M
    Oncol Rep; 2014 Nov; 32(5):1815-9. PubMed ID: 25174456
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Discrepancy between immunohistochemistry and sequencing for BRAF V600E in odontogenic tumours: Comparative analysis of two VE1 antibodies.
    Oh KY; Cho SD; Yoon HJ; Lee JI; Hong SD
    J Oral Pathol Med; 2021 Jan; 50(1):85-91. PubMed ID: 32939809
    [TBL] [Abstract][Full Text] [Related]  

  • 28. VE1 immunohistochemistry is an adjunct tool for detection of BRAF
    Rashid FA; Tabassum S; Khan MS; Ansari HR; Asif M; Sheikh AK; Sameer Aga S
    J Clin Lab Anal; 2021 Feb; 35(2):e23628. PubMed ID: 33305405
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Assessment of BRAF V600E (VE1) immunochemistry for the detection of BRAF V600E mutation in non-small cell lung carcinoma cytology specimens.
    Garcia A; Rivera Rolon MDM; Barkoh B; Chen W; Luthra R; Roy-Chowdhuri S
    Cancer Cytopathol; 2023 Jan; 131(1):50-57. PubMed ID: 36200799
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pleomorphic xanthoastrocytoma, anaplastic pleomorphic xanthoastrocytoma, and epithelioid glioblastoma: Case series with clinical characteristics, molecular features and progression relationship.
    Lin Z; Yang R; Zheng H; Li Z; Yi G; Wu Q; Yang C; Huang G
    Clin Neurol Neurosurg; 2022 Oct; 221():107379. PubMed ID: 35932588
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A novel, potentially targetable TMEM106B-BRAF fusion in pleomorphic xanthoastrocytoma.
    Hsiao SJ; Karajannis MA; Diolaiti D; Mansukhani MM; Bender JG; Kung AL; Garvin JH
    Cold Spring Harb Mol Case Stud; 2017 Mar; 3(2):a001396. PubMed ID: 28299358
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Desmoplastic non-infantile astrocytoma/ganglioglioma: rare low-grade tumor with frequent BRAF V600E mutation.
    Chatterjee D; Garg C; Singla N; Radotra BD
    Hum Pathol; 2018 Oct; 80():186-191. PubMed ID: 29902580
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Immunohistochemical detection of BRAF V600E mutant protein using the VE1 antibody in colorectal carcinoma is highly concordant with molecular testing but requires rigorous antibody optimization.
    Kuan SF; Navina S; Cressman KL; Pai RK
    Hum Pathol; 2014 Mar; 45(3):464-72. PubMed ID: 24529329
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clinical utility of immunohistochemistry for the detection of the BRAF v600e mutation in papillary thyroid carcinoma.
    Zagzag J; Pollack A; Dultz L; Dhar S; Ogilvie JB; Heller KS; Deng FM; Patel KN
    Surgery; 2013 Dec; 154(6):1199-204; discussion 1204-5. PubMed ID: 23931769
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pleomorphic Xanthoastrocytoma: Natural History and Long-Term Follow-Up.
    Ida CM; Rodriguez FJ; Burger PC; Caron AA; Jenkins SM; Spears GM; Aranguren DL; Lachance DH; Giannini C
    Brain Pathol; 2015 Sep; 25(5):575-86. PubMed ID: 25318587
    [TBL] [Abstract][Full Text] [Related]  

  • 36. BRAF mutation and anaplasia may be predictive factors of progression-free survival in adult pleomorphic xanthoastrocytoma.
    Tabouret E; Bequet C; Denicolaï E; Barrié M; Nanni I; Metellus P; Dufour H; Chinot O; Figarella-Branger D
    Eur J Surg Oncol; 2015 Dec; 41(12):1685-90. PubMed ID: 26454767
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Analysis of BRAF V600E mutation in 1,320 nervous system tumors reveals high mutation frequencies in pleomorphic xanthoastrocytoma, ganglioglioma and extra-cerebellar pilocytic astrocytoma.
    Schindler G; Capper D; Meyer J; Janzarik W; Omran H; Herold-Mende C; Schmieder K; Wesseling P; Mawrin C; Hasselblatt M; Louis DN; Korshunov A; Pfister S; Hartmann C; Paulus W; Reifenberger G; von Deimling A
    Acta Neuropathol; 2011 Mar; 121(3):397-405. PubMed ID: 21274720
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Diagnostic value of immunohistochemistry for the detection of the BRAF(V600E) mutation in papillary thyroid carcinoma: comparative analysis with three DNA-based assays.
    Ilie MI; Lassalle S; Long-Mira E; Bonnetaud C; Bordone O; Lespinet V; Lamy A; Sabourin JC; Haudebourg J; Butori C; Guevara N; Peyrottes I; Sadoul JL; Bozec A; Santini J; Capper D; von Deimling A; Emile JF; Hofman V; Hofman P
    Thyroid; 2014 May; 24(5):858-66. PubMed ID: 24417277
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Immunohistochemical detection of the BRAF V600E mutation in melanoma patients with monoclonal antibody VE1.
    Liu H; Li Z; Wang Y; Feng Q; Si L; Cui C; Guo J; Xue W
    Pathol Int; 2014 Dec; 64(12):601-6. PubMed ID: 25359093
    [TBL] [Abstract][Full Text] [Related]  

  • 40. BRAF V600E immunohistochemistry is reliable in primary and metastatic colorectal carcinoma regardless of treatment status and shows high intratumoral homogeneity.
    Bledsoe JR; Kamionek M; Mino-Kenudson M
    Am J Surg Pathol; 2014 Oct; 38(10):1418-28. PubMed ID: 24921639
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.